Anticoagulant therapy plays an important role in the prevention and treatment of arterial and
venous thrombosis Researchers and clinicians are becoming interested in using Factor Xa …

At least five arguments can be put forward to support the concept that selective inhibitors of
factor Xa might be superior to selective inhibitors of thrombin. It should be noted, however …

Anticoagulant therapy plays an important role in the prevention and treatment of pathologic
arterial and venous thrombosis. There is increasing enthusiasm in the inhibition of Factor Xa …

Unfractionated heparin (UFH) inhibits both factor Xa and factor IIa in the presence of
antithrombin III or AT. Low molecular weight heparins (LMWH) have a potent factor Xa …

Within recent years, considerable interest has arisen in the new anticoagulant and non–
anticoagulant actions of heparins and other glycosaminoglycans. In addition, oral direct …

Heparins and vitamin K antagonists have been the cornerstones of anticoagulation
treatment for several decades. Despite their effectiveness, these agents have limitations …

The conventional management of thrombotic disorders is based on the use of heparin, oral
anticoagulants, and aspirin. The development of low molecular weight heparins and the …

Activated factor Xa promotes coagulation by generating small amounts of thrombin in the
proximity of platelets, thus enhancing their activation, and by binding to factor Va on …

In recent years, the understanding of the causes and mechanisms of thromboembolic
disorders has rapidly grown. The established therapeutic strategies obviously have their …